Latest News
July 29
2010
Posted at 2:32:25 PM
News Post #: 33
Prevention and Control of Influenza with Vaccines: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2010
This report updates 2009 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine for the prevention and control of influenza. Highlights of the 2010 recommendations include 1) a recommendation that annual vaccination be administered to all persons aged ≥6 months for the 2010-11 influenza season; 2) a recommendation that children aged 6 months-8 years whose vaccination status is unknown or who have never received seasonal influenza vaccine before (or who received seasonal vaccine for the first time in 2009-10 but received only 1 dose in their first year of vaccination) as well as children who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine regardless of previous influenza vaccine history should receive 2 doses of a 2010–11 seasonal influenza vaccine (minimum interval: 4 weeks) during the 2010–11 season; 3) a recommendation that vaccines containing the 2010–11 trivalent vaccine virus strains A/California/7/2009 (H1N1)-like (the same strain as was used for 2009 H1N1 monovalent vaccines), A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens be used; 4) information about Fluzone High-Dose, a newly approved vaccine for persons aged ≥65 years; and 5) information about other standard-dose newly approved influenza vaccines and previously approved vaccines with expanded age indications. Vaccination efforts should begin as soon as the 2010-11 seasonal influenza vaccine is available and continue through the influenza season.
www.cdc.gov/mmwr/preview/mmwrhtml/rr59e0729a1.htm?s_cid=rr59e0729a1_e
July 28
2010
Posted at 9:59:35 AM
News Post #: 32
Influenza Map
A weekly update of influenza activity by state and territory: www.cdc.gov/flu/weekly/usmap.htm
July 28
2010
Posted at 9:58:34 AM
News Post #: 31
FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP), 2010
On October 16,
2009, the Food and Drug Administration licensed quadrivalent human
papillomavirus vaccine (HPV4; Gardasil, Merck & Co. Inc.) for use in males
aged 9 through 26 years for prevention of genital warts caused by human
papillomavirus (HPV) types 6 and 11. HPV4 had been licensed previously for use
in females aged 9 through 26 years for prevention of HPV 6, 11, 16, and
18-related outcomes (i.e., vaginal, vulvar, and cervical precancers and cancers
and genital warts). The Advisory Committee on Immunization Practices (ACIP)
recommends routine vaccination of females at age 11 or 12 years and catch-up
vaccination for females aged 13 through 26 years (1).
On October 21, 2009, ACIP provided guidance that HPV4 may be given to males
aged 9 through 26 years to reduce their likelihood of acquiring genital warts;
ACIP does not recommend HPV4 for routine use among males.
www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm
July 26
2010
Posted at 7:57:00 PM
News Post #: 29
Use of Anthrax Vaccine in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2009
These recommendations from the Advisory Committee on Immunization
Practices (ACIP) update the previous recommendations for anthrax
vaccine adsorbed (AVA) and reflect the status of anthrax vaccine
supplies in the United States. Substantial changes to these
recommendations include the following: 1) reducing the number of doses
required to complete the pre-event and preexposure primary series from
6 doses to 5 doses, 2) recommending intramuscular rather than
subcutaneous AVA administration for preexposure use, 3) recommending
AVA as a component of postexposure prophylaxis in pregnant women
exposed to aerosolized Bacillus anthracis spores, 4) providing guidance
regarding preexposure vaccination of emergency and other responder
organizations under the direction of an occupational health program,
and 5) recommending 60 days of antimicrobial prophylaxis in conjunction
with 3 doses of AVA for optimal protection of previously unvaccinated
persons after exposure to aero¬solized B. anthracis spores.
Download the full pdf
July 16
2010
Posted at 2:00:02 PM
News Post #: 28
Notes from the Field: Pertussis --- California, January -- June 2010
MMWR Weekly, Vol. 59, No. 26
The number of pertussis cases reported to the California Department of Public Health (CDPH) has increased substantially during 2010. The increase in cases was first noted in late March among patients admitted to a children's hospital. During January 1-- June 30, 2010, a total of 1,337 cases were reported, a 418% increase from the 258 cases reported during the same period in 2009.
www.cdc.gov/mmwr/preview/mmwrhtml/mm5926a5.htm
